The majority of the papers belonging to the special issue investigated the role of polymorphisms in treatment response. Indeed, the role of germline DNA variations in clinical outcome or in drug toxicity is undeniable. This is well reported by Ravegnini and collaborators that made a general portrait of imatinib response in gastrointestinal stromal tumor (GIST) describing both tumor and patient DNA contribution to the final outcome [6] . Similarly, Polillo et al. depicted the importance of polymorphisms in imatinib and other tyrosine kinase inhibitors response in chronic myeloid leukemia (CML) [4] . These studies highlighted that polymorphisms located in genes codifying for imatinib transporters, as ABCG2 or SLC22A, might be involved in the clinical response. Indeed, the active uptake of imatinib into GIST and CML cells is known to be mediated mainly by transporter proteins, as hOCT1, or OCTN, whereas the efflux is mediated by the ABC transporters, in particular ABCB1 or ABCG2 [20] [21] [22] [23] . In this regard, some studies have highlighted the influence of genetic polymorphisms in transporter genes and imatinib efficacy. Similarly, allelic variations in transporter genes seem to be important in the methotrexate treatment in rheumatoid arthritis patients as reported by Lima et al. [15] . Another underestimated aspect of precision medicine is gathered by three independent authors, Ruiz, Franca and Zaza [8] [9] [10] that take into consideration the impact of therapy personalization in transplanted patients. In particular, while Franca and Zaza reviewed the state of the art in hematopoietic stem cell and in renal transplantations, respectively [9, 10] , Ruiz reported an analysis on the impact of genetic polymorphisms in lung transplanted patients receiving mycophenolic acid or tacrolimus [8] .
In addition to the certain role of polymorphisms in treatment response, recently the involvement of epigenetic mechanisms in personalized medicine has been catching on. This theme is faced by Cacabelos and Duroux-Richard and their respective collaborators [11, 14] . Cacabelos, in particular, presented the epigenetics mechanisms in the Alzheimer disease (AD) and aging dealing with the three major regulatory elements-DNA methylation, histone modifications and miRNA regulation-responsible for the control of metabolic pathways at the molecular level [11] . The study highlighted that pharmacoepigenetic studies should be incorporated in drug development and personalized treatments. Duroux-Richard focused the analysis on miRNA profiling evaluation with the aim to identify novel biomarkers in systemic lupus erythematosus (SLE), [14] . The study identified a specific miRNA signature and provided a deeper insight into SLE immune-pathogenesis. With respect to miRNA deregulation, the field is attracting a growing research interest. Indeed, their alteration is often correlated with the rise and development of many diseases, including cancer, both in solid, hematopoietic malignancies. In this view, Simeon et al. gave a little summary of this crucial aspect in their review explaining an initial approach toward precise medicine in primary plasma cell leukemia (PCL) [5] ; the review describes the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia and discuss the genomic characteristics based on conventional approaches, such as karyotype and fluorescence in situ hybridization analyses, and new high-throughput technologies, such as SNP array, gene expression profiling, miRNA expression profiling, and whole exome sequencing [5] .
Overall, the sixteen studies included in this Special Issue illustrate how many steps in different disciplines have been covered from the achievement of the Human Genome Project.
At the moment, very few genotype-driven dose-optimization studies have prospectively assessed response rate, efficacy and toxicity, and have been translated into clinical practice. Currently, the evidences are still too sparse to provide a solid relationship between germline variants and drug response, largely due to the small size population under evaluation and lack of validated predictive polymorphisms. Furthermore, the identification of pharmacogenetic markers, transferable to clinical practice, may be complicated by the inability to currently take into account the effects of somatic genome, tumor heterogeneity, epigenetic factors; the possible existence of additional unidentified predictive factors can further complicate the application of pharmacogenetics. For these reasons, there is still an ongoing need for precision medicine. In this context, with the advent of next-generation techniques many progresses have been made, but we are still far from the goal to create an individualized treatment according to his/her genotype. Only with a huge effort both economic and research working, it will be possible to dock this pivotal turning point. We therefore strongly believe that multi-centric and multi-disciplinary works, led by laboratory researchers and clinicians in close collaboration will permit to advance our understanding and knowledge in precision medicine. In conclusion, to answer the question of how far is the goal toward a personalized medicine, despite the extensive studies and some promising results, it is still unclear when and how pharmacogenetic testing will be routinely integrated into patient management.
